Sinovac Biotech has submitted a Clinical Trial Application with the China FDA to commence human clinical trials for its vaccine against Avian influenza A(H7N9) virus. The CTA was officially accepted by CFDA on January 29. Once the CTA is approved, Sinovac is prepared to initiate the clinical trials in a timely manner.
- Health Care Industry
- Pharmaceuticals & Drug Trials
- Sinovac Biotech
- clinical trials